News >

Phase III Results Support Novel Focal Therapy for Low-Risk Prostate Cancer

Angelica Welch
Published: Wednesday, Feb 15, 2017

Dr. Mark Emberton

Mark Emberton, MD

Padeliporfin vascular-targeted photodynamic therapy, a novel tissue-preserving treatment, may offer men with low-risk prostate cancer a safe and effective alternative to either active surveillance or radical therapy, according to the results of a phase III trial published in The Lancet Oncology.

The authors noted that more research must be done, as there are unanswered questions of the long-term effect of tissue-preserving treatment on control rates of prostate cancer, as well as tissue that lies beyond the treatment zone. A long-term follow-up has been initiated within the patients who participated in this study.
Azzouzi AR, Vincendeau S, Barret E, et al. Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial [published online December 19, 2016]. Lancet Oncol. doi: 10.1016/S1470-2045(16)30661-1.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Publication Bottom Border
Border Publication